Fight CRC Clinical Trial Finder

Date Trial Added
View:
NCT ID Title Phase Date Added Location Prior IO Allowed CRC-directed Status Drugs Tags
NCT ID
NCT03155061
TitleStudy of ONO-4578 With and Without ONO-4538 in Subjects Advanced or Metastatic Solid Tumors Phase
Phase 1
Date Added
2017-05-16
Location
Japan
Prior IO Allowed
Yes
CRC-directed
No
Status
Active, not recruiting
Drugs
ONO-4538, ONO-4578, Opdivo
Tags
MSS/ MMRp
NCT ID
NCT02925234
TitleThe Drug Rediscovery Protocol (DRUP Trial) Phase
Phase 2
Date Added
2016-10-05
Location
Netherlands
Prior IO Allowed
Yes
CRC-directed
No
Status
Recruiting
Drugs
Abemaciclib, afatinib, Alectinib, Alpelisib, Atezolizumab and Bevacizumab, Axitinib, Cabozantinib, Crizotinib, Dabrafenib, Dabrafenib and trametinib, Dacomitinib, durvalumab, Entrectinib, Erdafitinib, Erlotinib, Ipilimumab and nivolumab, Lenvatinib, lorlatinib, Nilotinib, Nivolumab, Olaparib, palbociclib, panitumumab, Pembrolizumab, Regorafenib, ribociclib, Rucaparib, Sunitinib, Talazoparib, Trametinib, Trastuzumab and Pertuzumab (combination treatment), Vemurafenib and Cobimetinib (combination treatment), Vismodegib
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT04085185
TitleA Study Evaluating the Safety, Tolerability, and Initial Efficacy of IBI110 in Subjects With Advanced Malignant Tumors Phase
Phase 1
Date Added
2019-09-11
Location
China
Prior IO Allowed
Yes
CRC-directed
No
Status
Recruiting
Drugs
IBI110, IBI110+ Sintilimab, IBI110, Sintilinab
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT02617277
TitleSafety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours Phase
Phase 1
Date Added
2015-11-30
Location
Colorado, United States
Florida, United States
Tennessee, United States
Prior IO Allowed
Yes
CRC-directed
No
Status
Active, not recruiting
Drugs
AZD1775, MEDI4736
Tags
MSS/ MMRp
NCT ID
NCT04550897
TitleA Phase I/II Study With BM7PE Immunotoxin in Colorectal Cancer Patients Phase
Phase 1
Date Added
2020-09-16
Location
Norway
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Recruiting
Drugs
BM7PE
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT03368963
TitleTAS102 in Combination With NAL-IRI in Advanced GI Cancers Phase
Phase 1, Phase 2
Date Added
2017-12-11
Location
Georgia, United States
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Active, not recruiting
Drugs
Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT05291156
TitleCAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy Phase
Phase 2
Date Added
2022-03-22
Location
Italy
Prior IO Allowed
Yes
CRC-directed
Yes
Status
Recruiting
Drugs
Avelumab, cetuximab
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
NCT03476681
TitleStudy of NEO-201 in Solid Tumors Expansion Cohorts Phase
Phase 1, Phase 2
Date Added
2018-03-26
Location
Maryland, United States
Virginia, United States
Prior IO Allowed
Yes
CRC-directed
No
Status
Recruiting
Drugs
NEO-201 in combination with pembrolizumab
Tags
MSI-H/ MMRd, MSS/ MMRp
NCT ID
VAPER
TitleA study looking at using a vaccine and chemotherapy to treat advanced cancer Phase
Phase 1
Date Added
2015-11-17
Location
Prior IO Allowed
Yes
CRC-directed
No
Status
Active, not recruiting
Drugs
Celecoxib, Cyclophosphamide, imiquimod, vaccine
Tags
MSS/ MMRp
NCT ID
NCT03502733
TitleTesting the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma Phase
Phase 1
Date Added
2018-04-19
Location
Maryland, United States
Texas, United States
Prior IO Allowed
Yes
CRC-directed
No
Status
Active, not recruiting
Drugs
Copanlisib, Ipilimumab, Nivolumab, Aliqopa, Opdivo
Tags
MSS/ MMRp